182
Kronik HCV
S131.
28.
Charlton M, Gane E, Manns MP, Brown Jr RS, Curry MP, Kwo PY, et al. Sofosbuvir
and ribavirin for treatment of compensated recurrent hepatitis C virus infection
after liver transplantation. Gastroenterology 2015;148:108–117.
29.
Reddy RK, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et
al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with
post-transplant recurrence: preliminary results of a prospective, multicenter study.
Hepatology 2014;60:200A–201A.
30.
Mantry PS, Kwo PY, Coakley E, Te HS, Vargas HE, Brown RS, et al. High sustained
virologic response rates in liver transplant recipients with recurrent HCV
genotype 1 infection receiving ABT-450/r/ombitasvir plus dasabuvir plus ribavirin.
Hepatology 2014;60:298A.
31.
Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, et al.Evaluation
of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and
community treatment of a real-world, heterogeneous population. Hepatology
2014;60:220A.
32.
Brown RS, Reddy KRJ, O’Leary JG, Kuo A, Morelli G, Stravitz RT, et al. Safety
and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval
results from the HCV-TARGET longitudinal, observational study.Hepatology
2014;60:1269A.
33.
Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et
al. High rates of virological response and major clinical improvement during
sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing
cholestatic HCV recurrence after liver transplantation: the ANRS CO23 CUPILT
study. Hepatology 2014;60:207A.
34.
Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The
natural history of hepatitis C virus infection: host, viral, and environmental factors.
JAMA 2000;284:450-456.
35.
Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR,et al. Effect of human
immunodeficiency virus on hepatitis C virüs infection among injecting drug users. J
Infect Dis 1996;174:690-695.
36.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garc_ýa J,
Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin forchronic hepatitis C virus
infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
37.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:
a randomized study of treatment duration and ribavirin dose. Ann Intern Med
2004;140:346-355.
38.
Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al.
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA
2014;312:353-361.
39.
Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK,
et al. ombination therapy with telaprevir for chronic hepatitis C virus genotype 1
infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159:86-96.
40.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA
recommendations for testing, managing, and treating adults infected with hepatitis
C virus. Hepatology. 2015;62:932-54.
41.
Khatri A, Wang T, Wang H, Podsadecki T, Trinh R, Awni W, et al.Drug–drug
interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir,
